Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-05-29 09:53:26 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2468-1253(25)00059-7
文献链接:
其他信息:
出版社: Elsevier BV
作者: Yinghong Shi; Guohong Han; Jian Zhou; Xuetao Shi; Weidong Jia; Ying Cheng; Yongdong Jin; Xiangdong Hua; Tianfu Wen; Jianbing Wu; Shanzhi Gu; Yuxian Bai; Xiangcai Wang; Tao Zhang; Zhiyu Chen; Bixiang Zhang; Ming Huang; Hongming Liu; Yilei Mao; Ledu Zhou; Rui Wang; Yunfeng Shan; Wu Zhang; Tianqiang Song; Yabing Guo; Fuxiang Zhou; Bingfeng Shao; Mingjun Zhang; Bo Liang; Jinfang Zheng; Guoping Zhang; Jie Shen; Weiwen Su; Feng Zhang; Yifu He; Sheng Hu; Rong Liu; Chengwu Zhang; Shunli Shen; Hui Zeng; Tsang-En Wang; Wenzhi Guo; Yan Shen; Yajin Chen; Yong Li; J Samol; Hongtao Hu; Wenhua Zhang; Chengyou Du; Enxiao Li; Chao Liu; Choo Su Pin; Xun Li; Hao Xu; Jee-Fu Huang; Chunyi Hao; Jing Lv; Wei Wang; Qian Xu; Aobing Bai; Xiao Zhang; Bifeng Liu; Chunlei Jin; Jia Fan